JP2008538173A5 - - Google Patents

Download PDF

Info

Publication number
JP2008538173A5
JP2008538173A5 JP2007553353A JP2007553353A JP2008538173A5 JP 2008538173 A5 JP2008538173 A5 JP 2008538173A5 JP 2007553353 A JP2007553353 A JP 2007553353A JP 2007553353 A JP2007553353 A JP 2007553353A JP 2008538173 A5 JP2008538173 A5 JP 2008538173A5
Authority
JP
Japan
Prior art keywords
cancer
luca2
tumor
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007553353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538173A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/003382 external-priority patent/WO2006083852A2/en
Publication of JP2008538173A publication Critical patent/JP2008538173A/ja
Publication of JP2008538173A5 publication Critical patent/JP2008538173A5/ja
Pending legal-status Critical Current

Links

JP2007553353A 2005-01-31 2006-01-31 Ｌｕｃａ２およびそれに結合する抗体 Pending JP2008538173A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64900705P 2005-01-31 2005-01-31
PCT/US2006/003382 WO2006083852A2 (en) 2005-01-31 2006-01-31 Luca2 and antibodies that bind thereto

Publications (2)

Publication Number Publication Date
JP2008538173A JP2008538173A (ja) 2008-10-16
JP2008538173A5 true JP2008538173A5 (enExample) 2009-03-05

Family

ID=36777832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007553353A Pending JP2008538173A (ja) 2005-01-31 2006-01-31 Ｌｕｃａ２およびそれに結合する抗体

Country Status (5)

Country Link
US (2) US7847070B2 (enExample)
EP (1) EP1846032A4 (enExample)
JP (1) JP2008538173A (enExample)
CA (1) CA2596115A1 (enExample)
WO (1) WO2006083852A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
US8709816B2 (en) 2009-09-04 2014-04-29 Tohoku University Human renal disease marker substance
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US16006A (en) * 1856-11-04 Kocking-chaik
US43029A (en) * 1864-06-07 Improvement in explosive projectiles for ordnance
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (enExample) * 1974-03-08 1982-06-04
US4105603A (en) * 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
USRE30548E (en) * 1979-08-31 1981-03-17 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5753229A (en) * 1991-09-25 1998-05-19 Mordoh; Jose Monoclonal antibodies reactive with tumor proliferating cells
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP1473301A3 (en) * 1997-06-04 2005-01-26 Cornell Research Foundation, Inc. Betulinol derivatives
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US20020164715A1 (en) * 2000-07-10 2002-11-07 Lin Ji Chromosome 3p21.3 genes are tumor suppressors
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
ATE488530T1 (de) * 2002-06-19 2010-12-15 Raven Biotechnologies Inc Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
US6682904B1 (en) * 2002-08-15 2004-01-27 Deliatroph Pharmaceuticals, Inc. Specific inhibitors of hyaluronidase 2, and methods of identifying and using same
WO2005035548A1 (en) * 2003-10-10 2005-04-21 Meditech Research Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
JP2006014694A (ja) * 2004-07-05 2006-01-19 Mitsubishi Kagaku Iatron Inc ペプチド、その抗体及びその抗体の製法

Similar Documents

Publication Publication Date Title
JP2010508847A5 (enExample)
JP2008532488A5 (enExample)
JP2008529494A5 (enExample)
JP2005532050A5 (enExample)
US12453780B2 (en) Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
JP7682789B2 (ja) Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用
CN110913908B (zh) 靶向msln的三特异性蛋白质及使用方法
JP2010110329A5 (enExample)
AU2025201864A1 (en) Anti-cd24 compositions and uses thereof
CN111183156A (zh) 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法
JP2013529059A5 (enExample)
JP2020501531A5 (enExample)
JP2008508858A5 (enExample)
CN121159691A (zh) 间皮素结合蛋白质
JP2007532139A5 (enExample)
JP2023547323A5 (enExample)
JP2008526256A5 (enExample)
JP2005538701A5 (enExample)
JP2006507013A5 (enExample)
JP2012503203A5 (enExample)
JP2009297037A5 (enExample)
JP2008516970A5 (enExample)
JP2007536932A5 (enExample)
JP2018508214A5 (enExample)
JP2005514425A (ja) Ｍｕｃ１８抗原に対する抗体